dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

March 17, 2021: Immatics Biotechnologies GmbH

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Company to host conference call on Wednesday, March 17 at 8:30 am EST

  • First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation
  • Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust biological activity of infused T cell products
  • Treatment-emergent adverse events were transient and manageable
Please read the whole article here

Immatics Biotechnologies GmbH, News 2021
March 16, 2021: AC Immune SA
March 19, 2021: Cosmo Pharmaceuticals NV

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz